Conditions: Secondary Hyperparathyroidism Due to Renal Causes
Keywords: Hyperparathyroidism Hyperparathyroidism Secondary Paricalcitol Calcifediol Parathyroid hormone Renal transplantation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 148
Healthy volunteers: no

Brief summary:
To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation.

Detailed description:
The purpose of this study is to demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation.

Arms:
arm 1: Paricalcitol oral capsules. arm 2: Calcifediol oral drops.

Interventions: intervention 1: Paricalcitol intervention 2: Calcifediol
Intervention descriptions: intervention 1: 1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours. intervention 2: 5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.

Protocol document: